Funding for this research was provided by:
Électricité de France (EP 2002-03, EP 2004-03, RB 2016-22)
Fondation de France (2001009761 and 2005011201)
Ligue Contre le Cancer (PRE04/NA, PRE07/NA and PRE2015 LNCC/NA)
Mutuelle Générale de l'Education Nationale (N/A)
Institut National Du Cancer (INCa-9578, INCa-DGOS-4654)
Association pour la Recherche sur le Cancer (N/A, PJA 20151203365)
Agence Nationale de la Recherche (ANR-10-EQPX-03)
National Breast Cancer Foundation (N/A)
INSERM - Ministère de la Recherche (01P0751 - 01P0752 - 01P0753 - 01P0754 - 01P0755)
Ligue Comité du Maine et Loire (N/A)
ITMO Santé Publique - AVIESAN (AAP12-COH-110)
Text and Data Mining valid from 2018-04-17
Received: 5 December 2017
Accepted: 5 March 2018
First Online: 17 April 2018
Ethics approval and consent to participate
: Written informed consent for genetic studies and use of medical records for the present analyses was obtained from all participants enrolled in the Retro-AT, CoF-AT, GENESIS and kConFab research programs. The appropriate local ethics committee (Comité de Protection des Personnes [CCP] Ile-de-France III 2002/2006) and the French data protection authority (Commission Nationale de l’Informatique et des Libertés [CNIL]) approved the individual resource collections; Retro-AT, CoF-AT, and GENESIS study protocols; and the specific study on tumour material ofATMcarriers. The kConFab resource collection and the specific study on tumour material ofATMcarriers were approved by the Peter MacCallum Cancer Centre Ethics Committee and the Queensland Institute of Medical Research Human Research Ethics Committee.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.